[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Qinghai Red Cross Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":194},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,78,111,139,166],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100625496","phase-3-study-on-the-efficacy-and-safety-of-mecobalamin-in-preventing-taxane-related-peripheral-neuropathy-100625496",false,"NCT07423390","Study on the Efficacy and Safety of Mecobalamin in Preventing Taxane-related Peripheral Neuropathy","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed solid tumors, including but not limited to breast cancer, lung cancer, gastric cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and melanoma;\n2. Age ≥18 years;\n3. Scheduled to receive adjuvant or neoadjuvant taxane-based chemotherapy (including paclitaxel, nab-paclitaxel, or docetaxel; as monotherapy or in combination) for early-stage disease, or has advanced disease with no prior chemotherapy;\n4. Life expectancy ≥3 months;\n5. ECOG performance status 0-2;\n6. Adequate major organ function (cardiac, hepatic, renal, and bone marrow function);\n7. Willing and able to provide written informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n1. Severe impairment of major organ function such that the participant cannot tolerate standard-dose chemotherapy;\n2. Pre-existing peripheral neuropathy or a history of peripheral neuropathy;\n3. Skin conditions (e.g., severe palmoplantar keratoderma, active skin infection) that may interfere with assessment of CIPN symptoms;\n4. Recent use of medications that may alleviate CIPN symptoms;\n5. Inability to swallow, intestinal obstruction, or other conditions that may affect drug absorption;\n6. Known hypersensitivity or allergy to mecobalamin;\n7. Pregnant or breastfeeding women.","ALL","18 Years",{"count":18,"type":19},326,"ESTIMATED","INTERVENTIONAL",[22],"PHASE3","Some patients receiving taxane-based chemotherapy experience numbness, tingling, or pain in their hands and feet, known as chemotherapy-induced peripheral neuropathy (CIPN). This study aims to find out whether oral mecobalamin can prevent or reduce CIPN. Participants will be assigned to take mecobalamin or to receive no routine mecobalamin prevention during chemotherapy, and outcomes will be compared between groups.",[25,26],"Peripheral Neuropathy Due to Chemotherapy","Peripheral Neuropathy, Chemotherapy-induced",[28,29,30,31],"Chemotherapy induced peripheral neuropathy","Mecobalamin","Taxane","Prevention","RECRUITING","2026-04-25",{"date":35,"type":36},"2026-04-30","ACTUAL",{"date":38,"type":36},"2026-02-24",{"date":40,"type":19},"2029-05-31",{"name":42,"class":43},"Qinghai Red Cross Hospital","OTHER",4,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":15,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":20,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},"100630588","early-phase-1-hydromorphone-with-electroacupuncture-and-ear-acupoint-pressing-for-refractory-cancer-pain-100630588","NCT07489625","Hydromorphone With Electroacupuncture and Ear Acupoint Pressing for Refractory Cancer Pain","Observation on the Clinical Efficacy of Hydromorphone Hydrochloride Sustained-Release Tablets Combined With Electroacupuncture and Ear Acupoint Pressing Beans in the Treatment of Refractory Cancer Pain","Inclusion Criteria:\n\n1. Patients who meet the diagnostic criteria for cancer ;\n2. Diagnosis of refractory cancer pain;\n3. Aged 19 or 80 years;\n4. Expected survival period ≥3 months;\n5. Karnofsky Performance Status (KPS) score ≥30 and Quality of Life (QOL) score ≥20;\n6. No history of allergy to opioid analgesics;\n7. No intellectual or psychiatric disorders; normal comprehension ability,capable of cooperating with pain assessments and questionnaire completion;\n8. Provision of signed written informed consent.\n\nExclusion Criteria:\n\n1. Patients with pain clearly unrelated to the tumor itself;\n2. Patients with pain relief after standardized pharmacological treatment;\n3. Patients aged under 19 years or over 80 years;\n4. Patients with an expected survival of less than 3 months;\n5. Patients with a Karnofsky Performance Status (KPS) score \\\u003C 30 or Quality of Life (QOL) score \\\u003C 20;\n6. Pregnant or lactating women;\n7. Patients with intellectual disability, mental or consciousness disturbance, who are unable to assess pain accurately or complete questionnaire surveys;\n8. Patients with needle phobia or extreme resistance to acupuncture treatment;\n9. Patients with hypersensitivity to Semen Vaccariae (Wang Bu Liu Xing).","19 Years","80 Years",{"count":55,"type":19},30,[57],"EARLY_PHASE1","This trial aims to address refractory cancer pain (RCP). It will explore the synergistic efficacy and safety of hydromorphone hydrochloride sustained-release tablets (HHST) combined with electroacupuncture (EA) and ear acupoint pressing beans (EAPB) for RCP. Key outcomes will include dynamic changes in Numerical Rating Scale (NRS) scores, proportions of patients with effective analgesia (≥30% NRS reduction from baseline) and marked remission (≥50% NRS reduction from baseline), daily HHST dosage, breakthrough pain (BP) frequency, and drug-related adverse events (AEs) graded by CTCAE 5.0.",[60,61],"Refractory Cancer Pain","Cancer Pain",[63,64,65,66,67],"electroacupuncture","ear acupoint pressing beans","hydromorphone","refractory cancer pain","cancer pain","NOT_YET_RECRUITING","2026-03-18",{"date":71,"type":36},"2026-03-24",{"date":73,"type":19},"2026-03-07",{"date":75,"type":19},"2028-12-31",{"name":42,"class":43},1,{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":53,"enrollmentInfo":85,"targetDuration":87,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":96,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":77},"100586439","metabolomic-and-lipidomic-analysis-predicts-immunotherapy-related-adverse-events-in-gastric-cancer-patients-100586439","NCT06915389","Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients","Comprehensive Plasma Metabolomic and Lipidomic Profiling for Predictive Modeling and Biomarker Discovery of Immune-Related Adverse Events in PD-1\u002FPD-L1 Inhibitor-Treated Gastric Cancer Patients: A Prospective Cohort Study","Inclusion Criteria:\n\n* Age≥ 18 years\n\n  * ECOG PS 0-2\n\n    * Gastric cancer diagnosed by histology or cytology\n\n      * Untreatment with PD-1\u002FPD-L1 inhibitors\n\n        * Expected survival≥3 months\n\n          * Exhibits a favorable adherence to treatment and follow-up,demonstrates compliance with the research protocol, and willingly signs the informed consent form.\n\nExclusion Criteria:\n\n* Unable to obtain an organization or due to insufficient organizational material, unable to diagnose gastric cancer\n\n  * Refusal to receive PD-1\u002FPD-L1 inhibitor treatment\n\n    * Baseline (before immunotherapy) plasma samples are unavailable\n\n      * Combined with autoimmune diseases\n\n        * Baseline (before immunotherapy) there are severe diseases in the heart, lungs, thyroid gland and other organs\n\n          * Baseline (before immunotherapy) there are severe abnormalities in liver and kidney functions, pancreatic enzymes and other indicators\n\n            ⑦ Researchers posit that any condition deemed potentially harmful to the subjects or that might prevent subjects from meeting or adhering to the research requirements shall not be permissible for inclusion in this study",{"count":86,"type":19},100,"1 Year","OBSERVATIONAL","This study comprehensively examines metabolic and lipidomic dynamics in gastric cancer patients initiating PD-1\u002FPD-L1 inhibitor therapy, employing a longitudinal design with pre- and post-treatment patients. The primary objectives include identifying irAE-associated metabolic and lipid biomarkers, developing predictive risk models, and evaluating the prognostic value of these molecular profiles. The findings are expected to contribute significantly to personalized treatment strategies and improved clinical decision-making in immunooncology.",[91,92,93,94,95],"Gastric Cancer","Immunotherapy","Adverse Event","Metabonomics","Lipidomics",[97,98,99,100,101,102],"Immune-related adverse events (irAEs)","PD-1\u002FPD-L1 inhibitors","Gastric cancer","Biomarkers","Metabolic","Lipidomic","2025-04-03",{"date":105,"type":36},"2025-04-08",{"date":107,"type":36},"2025-02-22",{"date":109,"type":19},"2027-06-30",{"name":42,"class":43},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":4,"eligibilityCriteria":117,"healthyVolunteers":118,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":20,"phases":121,"briefSummary":122,"conditions":123,"keywords":126,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":77},"100582121","phase-3-efficacy-of-auricular-pressure-beans-with-electroacupuncture-and-estazolam-treating-insomnia-caused-by-cancer-100582121","NCT06859190","Efficacy of Auricular Pressure Beans with Electroacupuncture and Estazolam Treating Insomnia Caused by Cancer","Analysis of the Efficacy of Auricular Pressure Beans Combined with Electroacupuncture and Estazolam for the Treatment of Insomnia Induced by Cancer","Inclusion Criteria:\n\n1. Age 18 and above.\n2. The diagnosis of a malignant solid tumor was confirmed by pathological examination.\n3. Clinically diagnosed cancer-caused insomnia with insomnia symptoms lasting more than 1 month, more than 3 or more times per week.\n4. An Insomnia Severity Index (ISI) score of 8 or higher and meets the criteria for insomnia disorder as defined in the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition.\n5. No medications related to the treatment of insomnia have been used in the last 1 month.\n6. No serious dysfunction of the heart, liver, kidneys or other vital organs.\n7. Patients volunteered to participate in this study and signed an informed consent form.\n\nExclusion Criteria:\n\n1. Irregular sleep-wake cycles in jobs with shift demands or due to inconsistent work schedules.\n2. Inadequately treated for another sleep disorder (e.g., sleep disorder disorders such as sleep apnea obstruction syndrome, restless leg syndrome, etc.).\n3. Received acupuncture or auricular pressure bean therapy within the past 3 months.\n4. Estimated life expectancy is ≥3 months.\n5. Have a history of severe allergies, especially to the drugs or treatments used in this study.\n6. History of severe mental illness with a current episode.\n7. History of substance abuse or alcohol dependence.",true,{"count":120,"type":19},60,[22],"The core objectives of this study are to assess the short-term and long-term efficacy of auricular acupoint pressure beans combined with electroacupuncture and estazolam in the treatment of cancer-caused insomnia. The study aims to accurately compare the differences between this combination therapy and standard Western medicine in improving sleep quality and effectively alleviating anxiety and depression. Additionally, it will meticulously observe the safety of the combined treatment and record the occurrence and potential causative factors of any adverse reactions.",[124,125],"Cancer","Insomnia",[127,128,63,129,130],"cancer","auricular pressure beans","insomnia","estazolam","2025-03-23",{"date":133,"type":36},"2025-03-25",{"date":135,"type":36},"2025-03-01",{"date":137,"type":19},"2026-12-01",{"name":42,"class":43},{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":53,"enrollmentInfo":146,"targetDuration":4,"studyType":20,"phases":148,"briefSummary":150,"conditions":151,"keywords":153,"overallStatus":68,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":77},"100584605","phase-2-electroacupuncture-for-preventing-adverse-events-of-cancer-immunotherapy-100584605","NCT06891521","Electroacupuncture for Preventing Adverse Events of Cancer Immunotherapy","Electroacupuncture for Preventing Adverse Events Associated With Cancer Immunotherapy: A Prospective, Multicenter, Open-Label, Single-Arm Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 18 years, any gender, any nationality.\n2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n3. A definitive diagnosis of malignant tumor confirmed by pathology, and no previous treatment with PD-1\u002FPD-L1 inhibitors.\n4. Patients who are receiving their first treatment with PD-1\u002FPD-L1 inhibitors monotherapy, PD-1\u002FPD-L1 inhibitors combined with anti-angiogenic agents, or combined chemotherapy.\n5. Expected survival of more than 3 months.\n6. Normal bone marrow and organ function.\n7. Premenopausal women must use adequate contraception.\n8. Written informed consent obtained from the patient prior to enrollment.\n\nExclusion Criteria:\n\n1. Patients who have previously received or are currently receiving immunotherapy monotherapy, immunotherapy combined with chemotherapy, or immunotherapy combined with targeted therapy.\n2. Patients who have undergone acupuncture, radiotherapy, or surgery within 4 weeks prior to the start of treatment.\n3. Patients who have received any dose of systemic corticosteroid treatment within 72 hours prior to Day 1 of Cycle 1.\n4. Patients with active systemic autoimmune diseases within the past 2 years (such as but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, pituitaryitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; subjects with a history of vitiligo or asthma in childhood who have been in complete remission with no intervention in adulthood may be included; subjects requiring bronchodilator medical intervention should be excluded), diagnosed with immunodeficiency or treated with immunosuppressive therapy within the past week, human immunodeficiency virus (HIV) (+), history of non-infectious pneumonia treated with glucocorticoids, pneumonia, active tuberculosis, active hepatitis B or C virus infection, or currently undergoing any systemic treatment for active infections.\n5. Significant abnormal laboratory values (platelet count, absolute neutrophil count, free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone(TSH), adrenocorticotropic hormone (ACTH), morning cortisol, glycated hemoglobin (HbA1c), C-peptide, autoantibodies, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase, prothrombin time\u002Finternational normalized ratio (PT\u002FINR), serum bilirubin, amylase, lipase, CRP).\n6. Skin diseases or inflammatory skin reactions that may interfere with clinical trial outcomes.\n7. Patients who have developed lymphedema at the site of acupuncture stimulation after receiving any acupuncture treatment.\n8. Patients who fear electroacupuncture stimulation or are allergic to stainless steel needles.\n9. Patients with psychiatric disorders, or those taking any antipsychotic or antidepressant medications.\n10. Any unresolved skin toxicity caused by previous chemotherapy or radiotherapy, except for hair loss.\n11. Patients with diabetes.\n12. Any other diseases, metabolic disorders, physical examination results, or clinical laboratory findings that raise reasonable suspicion of a disease or condition that may affect the interpretation of the outcomes or put the participant at high risk for treatment complications.\n13. Pregnant or breastfeeding women, or women planning to become pregnant during the study period.\n14. Severe medical or psychiatric conditions.\n15. Any patient deemed unsuitable for enrollment by the investigator.",{"count":147,"type":19},123,[149],"PHASE2","This study aims to investigate the preventive effects of electroacupuncture on immune-related adverse events (irAEs) in patients with malignant solid tumors at the neoadjuvant stage, locally advanced, unresectable, or metastatic stages, who are receiving immune checkpoint inhibitors (ICIs) monotherapy, ICIs combined with anti-angiogenic agents, or ICIs combined with chemotherapy. The study will evaluate the efficacy, safety and mechanisms of electroacupuncture in preventing irAEs in a multicenter setting.",[124,152],"Adverse Events",[154,155,156,157],"Electroacupuncture","immunotherapy","immune-related adverse events (irAEs)","malignant tumors","2025-03-17",{"date":160,"type":36},"2025-03-24",{"date":162,"type":19},"2025-03-20",{"date":164,"type":19},"2028-06-01",{"name":42,"class":43},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":118,"sex":15,"minAge":16,"maxAge":53,"enrollmentInfo":173,"targetDuration":4,"studyType":20,"phases":175,"briefSummary":176,"conditions":177,"keywords":181,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":77},"100542116","phase-3-survival-with-olanzapine-in-patients-with-locally-advanced-or-metastatic-upper-gastrointestinal-and-lung-cancer-100542116","NCT06338683","Survival With Olanzapine in Patients With Locally Advanced or Metastatic Upper Gastrointestinal and Lung Cancer","Survival With the Addition of Olanzapine to Anticancer Therapy in Patients With Locally Advanced, Unresectable or Metastatic Gastric, Esophageal, Hepatopancreaticobiliary and Lung Cancer: a Randomized Clinical Trial","Inclusion Criteria:\n\n1. Aged 18 years or older;\n2. Eastern Cooperative Oncology Group performance status of 0-3;\n3. Stage III or IV inoperable or metastatic gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer and lung cancer confirmed by histology or cytology;\n4. Subjected to palliative systemic chemotherapy, regardless of first-line or second-line treatment;\n5. Expected survival ≥ 3 months;\n6. The patient is eligible for oral administration without dietary restrictions;\n7. Exhibits a favorable adherence to treatment and follow-up, demonstrates compliance with the research protocol, and willingly signs the informed consent form.\n\nExclusion Criteria:\n\n1. Weight loss and gain may be attributed to alternative factors, such as edema or ascites;\n2. Suffers from mental disorders or is under the medication of any antipsychotic or antidepressant drugs;\n3. History of central nervous system disorders (such as brain metastasis, epilepsy;\n4. Patients undergoing sustained administration of sedative medications or long-term hormonal therapy, individuals with chronic alcoholism, or those with substance dependence on medications;\n5. Prohibition of Olanzapine Intake for Contraindicated Individuals;\n6. History of clozapine-induced agranulocytosis because patients will be at increased risk for neutropenia with Olanzapine;\n7. Uncontrolled diabetes mellitus and Uncontrolled seizure disorder;\n8. Pregnant and Nursing women;\n9. Exclusion criteria include active participation in another interventional clinical trial, ongoing involvement in an observational (noninterventional) clinical trial, or being in the survival follow-up phase of an interventional clinical trial;\n10. Researchers posit that any condition deemed potentially harmful to the subjects or that might prevent subjects from meeting or adhering to the research requirements shall not be permissible for inclusion in this study.",{"count":174,"type":19},230,[22],"This study aims to assess the impact of adding olanzapine to nutritional advice and standard anti-tumor therapy on the survival and safety of patients with locally advanced, unresectable or metastatic gastric cancer, esophageal cancer, hepato-pancreaticobiliary cancer, and lung cancer. Researchers seek to determine whether olanzapine can improve progression-free survival (PFS), overall survival (OS), and objective response rate (ORR) in advanced cancer patients who received standard anti-tumor therapy, and investigate the relationship between olanzapine-induced weight changes and patient survival.",[178,179,180],"Advanced Cancer","Olanzapine","Progression Free Survival",[182,183,184,185],"advanced cancer","olanzapine","chemotherapy","progression free survival","2024-03-28",{"date":188,"type":36},"2024-03-29",{"date":190,"type":36},"2024-03-20",{"date":192,"type":19},"2028-03-20",{"name":42,"class":43},""]